Literature DB >> 16894066

Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data.

Tim F Oberlander1, William Warburton, Shaila Misri, Jaafar Aghajanian, Clyde Hertzman.   

Abstract

CONTEXT: Prenatal exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants and maternal depression both alter neonatal health, and distinguishing the effects of each influence remains challenging.
OBJECTIVE: To determine whether exposure to SSRIs and depression differs from exposure to maternal depression alone.
DESIGN: Using population health data, records of neonatal birth outcomes were linked to records of maternal health and prenatal maternal prescriptions for SSRIs.
SETTING: Population of British Columbia, Canada. PARTICIPANTS: Mothers and their infants, representing all live births during a 39-month period (N = 119,547) (1998-2001). MAIN OUTCOME MEASURES: Outcomes from infants of depressed mothers treated with SSRIs (SE-D) were compared with outcomes from infants of depressed mothers not treated with medication (DE) and nonexposed controls. To control for maternal mental illness severity, propensity score matching was used to identify a comparison group of DE mothers who were similar to the SE-D mothers in characteristics in the year preceding and during pregnancy.
RESULTS: Fourteen percent of mothers were diagnosed as having depression during their pregnancy, and the incidence of prenatal SSRI exposure increased from 2.3% to 5.0% during a 39-month period. Birth weight and gestational age for SE-D infants were significantly less than for DE infants, as was the proportion of infants born at less than 37 weeks (95% confidence interval [CI], -1 to -64, -0.25 to -0.45, and -0.009 to -0.04, respectively), although differences in the incidence of birth weight less than the 10th percentile for gestational age were not significant. An increased proportion of SE-D infants had neonatal respiratory distress (13.9% vs 7.8%), jaundice (9.4% vs 7.5%), and feeding problems (3.9% vs 2.4%) compared with DE infants (95% CI of difference, 0.042-0.079, 0.003-0.334, and 0.005-0.025, respectively). When outcomes were compared between SE-D and propensity score-matched DE neonates, SE-D was associated with increased incidence of birth weight below the 10th percentile and rates of respiratory distress.
CONCLUSION: With linked population health data and propensity score matching, prenatal SE-D exposure was associated with an increased risk of low birth weight and respiratory distress, even when maternal illness severity was accounted for.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16894066     DOI: 10.1001/archpsyc.63.8.898

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  147 in total

1.  A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction.

Authors:  Nancy K Grote; Jeffrey A Bridge; Amelia R Gavin; Jennifer L Melville; Satish Iyengar; Wayne J Katon
Journal:  Arch Gen Psychiatry       Date:  2010-10

2.  Dose-dependent effects of neonatal SSRI exposure on adult behavior in the rat.

Authors:  Sharonda S Harris; Dorota Maciag; Kimberly L Simpson; Rick C S Lin; Ian A Paul
Journal:  Brain Res       Date:  2011-10-20       Impact factor: 3.252

Review 3.  Exposed or not exposed? Exploring exposure classification in studies using administrative data to investigate outcomes following medication use during pregnancy.

Authors:  Luke E Grzeskowiak; Andrew L Gilbert; Janna L Morrison
Journal:  Eur J Clin Pharmacol       Date:  2011-11-13       Impact factor: 2.953

Review 4.  Investigating outcomes following the use of selective serotonin reuptake inhibitors for treating depression in pregnancy: a focus on methodological issues.

Authors:  Luke E Grzeskowiak; Andrew L Gilbert; Janna L Morrison
Journal:  Drug Saf       Date:  2011-11-01       Impact factor: 5.606

5.  Behavioural effects of fetal antidepressant exposure in a Norwegian cohort of discordant siblings.

Authors:  Ragnhild Eek Brandlistuen; Eivind Ystrom; Malin Eberhard-Gran; Irena Nulman; Gideon Koren; Hedvig Nordeng
Journal:  Int J Epidemiol       Date:  2015-04-14       Impact factor: 7.196

6.  Concerns regarding antidepressant drug use during pregnancy.

Authors:  Adam C Urato
Journal:  J Psychiatry Neurosci       Date:  2006-11       Impact factor: 6.186

7.  Prescribing antidepressants to pregnant women: what is a family physician to do?

Authors:  Adrienne Einarson; Gideon Koren
Journal:  Can Fam Physician       Date:  2007-09       Impact factor: 3.275

8.  Examining the Reversibility of Long-Term Behavioral Disruptions in Progeny of Maternal SSRI Exposure.

Authors:  Susan E Maloney; Shyam Akula; Michael A Rieger; Katherine B McCullough; Krystal Chandler; Adrian M Corbett; Audrey E McGowin; Joseph D Dougherty
Journal:  eNeuro       Date:  2018-07-09

9.  The effects of maternal depression and use of antidepressants during pregnancy on risk of a child small for gestational age.

Authors:  Hans Mørch Jensen; Randi Grøn; Ojvind Lidegaard; Lars Henning Pedersen; Per Kragh Andersen; Lars Vedel Kessing
Journal:  Psychopharmacology (Berl)       Date:  2013-03-02       Impact factor: 4.530

10.  Association of Panic Disorder, Generalized Anxiety Disorder, and Benzodiazepine Treatment During Pregnancy With Risk of Adverse Birth Outcomes.

Authors:  Kimberly Ann Yonkers; Kathryn Gilstad-Hayden; Ariadna Forray; Heather S Lipkind
Journal:  JAMA Psychiatry       Date:  2017-11-01       Impact factor: 21.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.